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Abstract
Background: The clinical practice of stroke prevention in atrial fibrillation (AF) with direct oral anticoagulants
(DOACS) differs from anticoagulation in randomized trial patients. We investigated the risk of thromboembolism,
bleeding, and drug discontinuation in a hospital-based real-world setting.
Methods: All-comer patients with non-valvular AF were recruited into a registry at an academic tertiary care center.
After informed consent, patients underwent a personal structured interview including medical history, past and
current anticoagulation, and returned for follow-up after 6–12 months.
Results: The registry comprised 282 patients (42% women, median age 71 years) with a median CHA2DS2-Vasc-Score
of 4 (25. to 75. percentile 2.5–5), who were prospectively followed 285 days in median. At inclusion, 118 patients took
vitamin-K-antagonists, 33 dabigatran, 87 rivaroxaban, 30 apixaban, 5 low-molecular-weight heparin, and 9 were on no
anticoagulant. Occurrence of stroke (rate 2.8/100 patient-years), was associated with prior stroke (hazard ratio [HR] 18.5,
95% confidence interval 2.16–159), increased HbA1c (HR per 1% increase 1.71, 1.20–2.45) and borderline significantly
associated with vascular disease (HR 8.33, 0.97–71.3). Further we observed a high rate of major bleeding (2.8/100
patient-years), clinically relevant non-major bleeding (4.1/100 patient-years), and venous thromboembolism (2.8/100
patient-years). Anticoagulation was discontinued by 80 patients (36.9/100 patient-years), and diabetes (HR 2.31, 1.32–4.
02), history of bleeding (HR 2.51, 1.44–4.37) and elevated leucocyte count (HR per 1G/l increase 1.02, 1.00–1.05) were
associated with increased risk of discontinuation.
Conclusions: In this hospital-based registry, patients with atrial fibrillation had an increased risk of thromboembolic
events despite anticoagulation. The low drug persistence may be attributable to distinct comorbid conditions and
bleeding complications.
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Background
The increased risk of stroke and systemic embolism in
patients with non-valvular atrial fibrillation (AF) can be
attenuated with continuous oral anticoagulation treatment
[1]. Direct oral anticoagulants (DOACs), including the
direct thrombin inhibitor dabigatran and the direct factor
Xa inhibitors rivaroxaban, apixaban, and edoxaban, have
shifted the paradigm of anticoagulation treatment from
routine drug monitoring and dose adjustment to a one-
size-fits-all strategy, and changed clinical practice of oral
anticoagulation. Real-world data have confirmed the effi-
cacy and safety of DOACs for stroke prevention [2, 3].
However, in a hospital-based patient population with AF,
comorbid conditions, comedications and surgical interven-
tions may complicate treatment with anticoagulant drugs,
which has not been specifically addressed in previous real-
world investigation.
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Furthermore, there is still concern that the ease of drug
administration and clinical management with DOACs
may not guarantee better persistence on treatment in a
real-world setting. Drug persistence is defined as the total
time a patient stays on a prescribed medication and
reduced persistence increases the risk of stroke [4, 5]. In
the randomized controlled trials that led to the licensing
of DOACs for stroke prevention in AF, 20.7%–34.3% of
patients receiving DOACs discontinued drug treatment
during the study period and 16.6%–34.4% discontinued
the control treatment, warfarin [6–9]. However, drug per-
sistence in clinical trials may be completely different from
real-world persistence, because there are different incen-
tives for remaining on treatment in real-world patients.
We aimed to examine the characteristics of non-valvular
AF patients in a hospital-based setting and investigate risk
factors for occurrence of thromboembolic events, bleeding
episodes and drug persistence while on anticoagulant treat-
ment, as well as reasons for drug discontinuation.
Methods
Patients
Patients with non-valvular AF referred to the Clinical
Division of Hematology and Hemostaseology were
recruited into a hospital-based, prospective registry from
July 2013 to May 2016. Inclusion criteria were confirmed
diagnosis of AF by a 12-channel, resting electrocardio-
gram (ECG), willingness to comply with study procedures,
and written informed consent. The study has approval of
the local ethics committee. There were no exclusion or
selection criteria concerning anticoagulation treatment,
medical history, risk of stroke, or bleeding. After obtaining
informed consent for study participation, a study investi-
gator performed a personal structured interview with each
patient, recorded the medical history and a detailed antic-
oagulation history. Patients returned for voluntary, sched-
uled follow-up visits 6 and 12 months after recruitment.
Baseline assessment of patient characteristics
All baseline patient data was recorded from personal
interviews and verified against medical records. The
structured interview included a detailed medical history,
especially concerning prior thromboembolic events, and
a detailed record of previous periods of anticoagulation
treatment and associated complications. During baseline
data collection, a history of vascular disease was defined
as arterial disease of any degree including coronary heart
disease, peripheral artery disease, and carotid artery
disease. Cancer was defined as any history of malignancy
or active malignancy at study inclusion with the excep-
tion of basalioma. Patients were anticoagulation naive at
baseline if they had not received continuous anticoagula-
tion treatment previously for longer than 3 months. The
baseline kidney function was calculated on the grounds
of the estimated glomerular filtration rate (eGFR) and
isotope-dilution mass spectrometry (IDMS) traceable
serum creatinine levels using the Modification of Diet in
Renal Disease (MDRD) equation. The risk of stroke was
assessed with the CHA2DS2-Vasc score and the risk of
bleeding with the HAS-BLED score.
Definition of events during prospective observation
Bleeding outcomes were classified according to the rec-
ommendations of the Scientific and Standardization
Committee of the International Society of Thrombosis
and Hemostasis. Major bleeding was defined as clinically
overt bleeding with fatal outcome, involvement of a crit-
ical anatomic site, fall in hemoglobin concentration of
more than 2 g/dl, transfusion of >2 units of whole blood
or packed red blood cells, or leading to permanent
disability [10]. Clinically relevant non-major (CRNM)
bleeding was defined as overt bleeding not meeting
criteria for major bleeding but requiring medical inter-
vention, hospitalization, temporary interruption or de-
layed dosing of anticoagulation, pain, or impairment of
daily activities [11]. Minor bleeding was defined as any
other bleeding not meeting the above criteria. Venous
thromboembolism (VTE) was defined as objectively con-
firmed deep vein thrombosis (DVT) or pulmonary embol-
ism (PE). Stroke was defined as the sudden onset of a
distinct focal neurologic deficit in a location consistent
with the territory of a major cerebral artery and conclusive
imaging evidence. In the absence of imaging evidence, but
conclusive neurological symptoms confirmed by a special-
ist in neurology, we recorded a transient ischemic attack
(TIA). All events were internally validated according to
the criteria listed above.
Definition of anticoagulation persistence
Drug persistence was defined as the time in weeks from
the initiation of anticoagulation until discontinuation of
treatment [12]. Only patients who initiated anticoagula-
tion at the time of recruitment were included in the per-
sistence analysis. The percentage of patients remaining
on the baseline anticoagulant was calculated for 6 and
12 months as well as the annualized discontinuation-
rate. The end of anticoagulation persistence was defined
as the permanent cessation of anticoagulation treatment
or switching from one anticoagulant to a different anti-
coagulant, but did not include pausing anticoagulation
treatment for a limited time of less than 1 month.
Statistical methods
Baseline patient characteristics of the registry cohort
were described as absolute and relative frequencies or
with median and 25th to 75th percentile, respectively for
categorical and continuous data. The baseline group
comparisons between DOAC and vitamin-K-antagonist
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(VKA) patients were calculated with the Mann–Whitney-
U test for categorical parameters or the chi2 test for con-
tinuous variables. An asymptotic two-sided p-value of
smaller than 0.05 was considered statistically significant.
The risks of stroke, TIA, or systemic embolism, bleeding,
and drug discontinuation were calculated with the univari-
able Cox proportional hazards model. All calculations
were performed with SPSS (Windows Version 23.0; IBM
Corp., Armonk, NY, http://www.ibm.com). Risk of discon-
tinuation was only calculated with patients who initiated a
new anticoagulation therapy at study inclusion.
Results
Baseline registry characteristics
The registry includes 282 patients (118 [42%] women,
164 [58%] men) with ECG-confirmed diagnosis of AF
and a median age of 71 years (25th to 75th percentile 65
– 77 years). At baseline, 118 patients (41.8%) were on
VKA, 33 patients (11.7%) on dabigatran, 87 (30.9%) on
rivaroxaban, 30 (10.6%) on apixaban, 5 patients (1.8%)
on long-term low-molecular-weight heparin (LMWH)
and 9 patients (3.2%) did not take any anticoagulant
drug. The baseline characteristics of the full registry and
respective to groups of patients on each anticoagulant
are shown in Table 1. DOACs were more frequently pre-
scribed to patients with more recently diagnosed AF and
to patients previously naïve to anticoagulation treatment
(Table 1). Patients with history of CRNM or major
bleeding, with age between 65–75 years were also more
frequently on DOAC treatment. Patients older than
75 years were more often on VKA, while patients on
DOACs, especially rivaroxaban and apixaban, tended to
have lower hemoglobin and hematocrit levels than pa-
tients on VKA. Patients with lower eGFR, however,
tended to take VKA (Table 1).
Prospective outcomes
Prospective follow-up was available for 269 patients and
13 patients (4.6%) were lost to follow-up. The median ob-
servation time was 285 days (227–405 days) (minimum
1 day, maximum 966) for a total of 217 patient-years of
observation time. During follow-up, 6 (2.2%) cardioem-
bolic events occurred (4 ischemic strokes, 1 TIA, 1 sys-
temic embolism), corresponding to an event-rate of 2.8
per 100 patient-years. Of these events, 4 occurred while
on VKA, 1 while on rivaroxaban, and 1 while on triple
therapy with VKA.
In univariable Cox regression, patients with a history
of stroke, TIA, or systemic embolism had an 18-fold in-
creased risk of a new stroke, TIA or systemic embolism
(hazard ratio [HR] 18.5, 95% confidence interval [CI]
2.16–159, p = 0.008), patients with vascular disease had a
borderline significant 8.3-fold increased risk of stroke
(HR 8.3, 95% CI 0.97–71.3, p = 0.05), and for every 1%
increase in HbA1c the risk of stroke increased 1.7-fold
(95% CI 1.20–2.45, p = 0.003) (Table 2). For every one
point added to the CHA2DS2-Vasc score the risk of
stroke doubled (HR 2.06, 95% CI 1.27–3.35, p = 0.004).
One myocardial infarction occurred while on VKA, and
6 VTE events occurred (4 DVT, 2 PE), corresponding to
an event-rate of 2.8 per 100 patient-years. One VTE
event occurred while on rivaroxaban therapy, 2 during
rivaroxaban pause, 1 during VKA treatment, 1 during
VKA pause, and 1 after discontinuation of rivaroxaban.
Major bleeding events occurred in 6 patients (3 intraocular
hemorrhages, 2 intraabdominal bleedings with massive
blood loss and/or transfusions, 1 subdural hematoma) and
CRNM bleeding events occurred in 9 patients (5
gastrointestinal [GI] bleeds, 4 other bleeds requiring
hospitalization). The event rate for major bleeding
was 2.8 per 100 patient-years and for CRNM bleeding
4.1 per 100 patient-years. Minor bleeding events oc-
curred in 43 patients and 15 patients died during
follow-up of causes unrelated to atrial fibrillation or
anticoagulation. The results of our analysis revealed
no statistically significant risk factor for bleeding that
occurred during follow-up.
Anticoagulation persistence
The median persistence was 32 weeks (25th to 75th per-
centile: 12 to 46 weeks) and 80 patients (29.7%) discontin-
ued the anticoagulation therapy, which they had received
at baseline. This corresponds to a rate of discontinuation
of 36.9 per 100 patient-years. After 6 months, the overall
drug persistence of the baseline anticoagulant was 76.7%
and after 12 months further reduced to 54.7%. There was
no difference in the persistence between patients receiving
DOACs and VKA (Fig. 1). The most frequent reasons for
discontinuing anticoagulation were patient-reported end
of AF and permanent return to sinus rhythm (20%), emer-
gence of a new contraindication for current anticoagula-
tion treatment (15%) (e.g. mechanical heart valve),
physician’s recommendation (12.5%), and occurrence of
major or CRNM bleeding events (11.3%) (Table 3). The
choice for an alternative anticoagulant after discontinu-
ation of the baseline anticoagulant drug was evenly
distributed between VKA, rivaroxaban, apixaban or no
anticoagulant at all (Table 3). In regression analysis, pa-
tients with diabetes had a 2.3-fold increased risk of discon-
tinuation (95% CI 1.32 to 4.02), patients with history of
bleeding had a 2.5-fold increased risk (95% CI 1.44 to
4.37) and per 1 G/l increase in leucocyte count the risk of
discontinuation increased by 2% (HR = 1.02, 95% CI 1.00
to 1.05).
Discussion
In this analysis of a real-world, tertiary-care, hospital-
based registry of patients with atrial fibrillation, the rate
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of cardioembolic events (2.8 per 100 patient-years) was
higher than in the randomized controlled trials for
stroke prevention in AF. In RE-LY, ROCKET-AF, ARIS-
TOTLE and ENGAGE-AF-TIMI48, 1.6–2.2% of patients
randomized to warfarin and 1.11–2.04% for patients ran-
domized to the study drugs had strokes or systemic
embolisms per year [6–9]. The stroke-rate in our study was
also higher than in other data sets of real-world AF
Table 1 Baseline cohort characteristics
Characteristic Full cohort
(N = 282)
VKA (N = 118) Dabigatran (N = 33) Rivaroxaban (N = 87) Apixaban (N = 30)
p* p* p*
Age 71 (65–77) 73 (67–79) 73 (68–77) 0.8 71 (66–75) 0.1 71 (64–75) 0.04
Female sex 116 (43.1) 47 (41.6) 11 (34.4) 0.5 30 (37.0) 0.5 22 (75.9) 0.001
BMI 27.0 (24.5–30.4) 27.3 (24.9–31.2) 27.3 (25.0–31.0) 0.7 27.0 (24.0–31.1) 0.5 26.9 (22.2–28.3) 0.09
Type of AF
Recently diagnosed 52 (18.4) 10 (8.5) 8 (24.2) 0.04 16 (18.4) 0.2 13 (43.3) <0.001
paroxysmal 131 (46.5) 60 (50.8) 10 (30.3) 0.05 42 (49.4) 0.8 12 (40.0) 0.3
persisting 19 (6.7) 9 (7.6) 1 (3.0) 0.4 7 (8.6) 0.7 1 (3.3) 0.5
permanent 80 (28.4) 39 (33.1) 14 (42.4) 0.3 22 (27.2) 0.4 4 (13.3) 0.04
Time since AF diagnosis, years 4 (1–8) 4 (2–9) 5 (0.1–9) 0.5 3 (1–10) 0.1 2 (0–6) 0.01
History of electrical cardioversion 83 (30.9) 40 (35.4) 10 (31.3) 0.7 21 (25.9) 0.2 9 (31.0) 0.7
History of ablation 35 (13.0) 15 (13.3) 5 (15.6) 0.7 13 (16.0) 0.6 1 (3.4) 0.1
Family history of AF 33 (12.3) 13 (11.5) 3 (9.4) 0.7 10 (12.3) 0.9 7 (24.1) 0.08
Medical history
Congestive heart failure 81 (30.1) 34 (30.1) 13 (40.6) 0.3 24 (29.6) 0.9 8 (27.6) 0.8
Hypertension 227 (84.4) 99 (87.6) 30 (93.8) 0.3 65 (80.2) 0.2 26 (89.7) 0.8
Age≥ 75 years 98 (36.4) 53 (46.9) 13 (40.6) 0.5 23 (28.4) 0.009 8 (27.6) 0.06
Age 65–74 years 114 (42.4) 41 (36.3) 14 (43.8) 0.4 43 (53.1) 0.02 13 (44.8) 0.4
Diabetes 81 (28.7) 31 (27.4) 10 (31.3) 0.4 22 (27.2) 0.7 8 (27.6) 0.9
Stroke / TIA / systemic embolism 55 (20.4) 22 (19.5) 7 (21.9) 0.8 20 (24.7) 0.4 4 (13.8) 0.5
Vascular disease 96 (35.7) 41 (36.3) 13 (40.6) 0.7 28 (34.6) 0.8 11 (37.6) 0.9
CHA2DS2-VASC Score 4 (2.5–5) 4 (3–5) 4 (3–5) 0.9 3 (2–5) 0.3 4 (3–4.5) 0.4
HAS-BLED Score 2 (1–3) 2 (1–2) 2 (1–3) 0.7 2 (1–3) 0.2 2 (1–3) 0.5
Abnormal liver or kidney function 52 (19.3) 24 (21.2) 5 (15.6) 0.5 18 (22.2) 0.9 5 (17.2) 0.6
CRNM bleeding 13 (4.8) 1 (0.9) 2 (6.3) 0.06 4 (4.9) 0.08 4 (13.8) 0.001
Major bleeding 10 (3.7) 1 (0.9) 5 (15.6) <0.001 4 (4.9) 0.08 0 0.6
Venous thromboembolism 22 (8.2) 7 (6.2) 3 (9.4) 0.5 9 (11.1) 0.2 3 (10.3) 0.4
Cancer 58 (21.6) 19 (16.8) 9 (28.1) 0.2 19 (23.5) 0.3 6 (20.7) 0.6
OAC-naïve at baseline 18 (6.7) 4 (3.5) 2 (6.3) 0.5 6 (7.4) 0.2 4 (13.8) 0.03
Aspirin comedication 58 (21.6) 23 (20.4) 5 (15.6) 0.6 19 (23.5) 0.6 6 (20.7) 0.9
Clopidogrel comedication 14 (5.2) 9 (8.0) 2 (6.3) 0.7 3 (3.7) 0.2 0 0.1
Baseline laboratory parameters
Platelet count 214 (176–264) 211 (180–251) 203 (172–239) 0.4 215 (174–286) 0.3 238 (177–275) 0.4
Hemoglobin 13.2 (11.8–14.4) 13.5 (12.5–14.8) 13.2 (11.8–15.2) 0.3 12.7 (11.4–14.1) 0.002 12.8 (11.0–14.1) 0.05
Hematocrit 39.5 (35.1–42.8) 40.3 (37.4–43.9) 39.5 (34.9–42.6) 0.2 38.5 (33.6–41.0) 0.001 38.8 (33.9–41.2) 0.03
Leucocyte count 6.8 (5.7–8.5) 6.8 (5.7–7.9) 7.0 (6.0–8.6) 0.3 6.9 (5.7–8.9) 0.3 6.4 (5.2–7.9) 0.3
eGFR (ml/min/1.73 m2) 65.2 (53.3–79.6) 60.4 (49.5–74.3) 71.2 (58.4–91.8) 0.03 66.8 (56.2–82.1) 0.01 65.8 (56.6–73.1) 0.2
Footnote: * Mann–Whitney-U test or chi2 p-value for asymptomatic two-sided difference between respective DOAC group and VKA group, statistically significant
p-values in bold print
Abbreviations: AF atrial fibrillation, VKA Vitamin-K-antagonist, BMI body-mass-index, TIA transient ischemic attack, CRNM bleeding clinically relevant non-major bleeding,
OAC oral anticoagulation, eGFR estimated glomerular filtration rate
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patients. Graham et al. reported a stroke rate of 1.1 per 100
patient years for dabigatran and 1.4 for warfarin in a data-
base of US Medicare patients [13]. Korenstra et al. found a
rate of stroke of 0.8% per year for VKA and 1.0% per year
for dabigatran outpatients [14], and Hecker et al. reported
an event rate of 2.0 per 100 patient-years in rivaroxaban
patients in daily-care [15]. In a recent report from the
GARFIELD-AF registry, the rate of stroke was 1.25 per 100
patient-years [16]. Not surprisingly, these cohorts had lower
frequencies of risk factors for strokes, including a prior
history of stroke, a history of vascular disease, diabetes and
a decreased CHA2DS2-Vasc Score, compared to our co-
hort. This is confirmation that a stroke risk evaluation is
clinically meaningful in a hospital-based setting. We also
observed a rate of myocardial infarction of 0.5 per 100
patients-years and a rate of VTE of 2.8 per 100 patient-
years. Firstly, it is interesting that a cohort reported by
Beyer-Westendorf et al. from a population of primary-care
AF patients with similar baseline stroke risk factors and
similar stroke rate had no VTE events at all [2]. Thus, the
risk of VTE in AF patients, especially when medically ill or
frail, should not be neglected. Secondly, a closer inspection
of the circumstances under which VTE events occurred, re-
vealed that the majority occurred during temporary pausing
of the anticoagulation therapy. Thus, VTE events may have
been avoidable with a proper bridging strategy or minimiz-
ing of the anticoagulation pause. We would like to interpret
this signal as a call to action on emphasizing educational
programs on safe and efficacious anticoagulation manage-
ment during interventions, operations, and hospitalizations.
Major bleeding events occurred with a rate of 2.8 per
100 patient-years and CRNM bleeding events with a rate
of 4.1 per 100 patient-years. The rate of major or CRNM
bleeding events was, however, not elevated in our cohort
compared to some other real-world registries despite a
median age of 71 years and a history of severe bleeding
complications in 8.5% of patients. This may be an indi-
cation that bleeding risk evaluation in medically ill
Table 2 Univariable Cox regression analysis of risk factors for the outcomes stroke, bleeding, and drug discontinuation
Hazard of stroke, TIA, systemic
embolism (N = 269)
Hazard of CRNM or major bleed
(N = 269)
Hazard of anticoagulant
discontinuation (N = 144)
Characteristic Hazard ratio
(95% confidence interval)
p-value Hazard ratio
(95% confidence interval)
p-value Hazard ratio
(95% confidence interval)
p-value
Agea 0.98 (0.90–1.06) 0.59 1.03 (0.97–1.09) 0.30 0.99 (0.96–1.02) 0.54
Female sex 6.45 (0.75–55.2) 0.09 0.95 (0.36–2.56) 0.93 1.01 (0.59–1.75) 0.96
BMIa 0.96 (0.81–1.13) 0.63 1.00 (0.92–1.10) 0.96 0.99 (0.94–1.04) 0.65
Medical history
Congestive heart failure 2.00 (0.40–9.94) 0.40 1.15 (0.42–3.18) 0.78 1.28 (0.73–2.23) 0.39
Hypertension 24.2 (0.00–999) 0.60 23.8 (0.01–999) 0.42 0.60 (0.28–1.28) 0.18
Diabetes 2.42 (0.49–12.0) 0.28 1.13 (0.39–3.27) 0.82 2.31 (1.32–4.02) 0.003
Stroke/TIA/systemic embolism 18.5 (2.16–159) 0.008 0.76 (0.22–2.69) 0.67 0.76 (0.38–1.53) 0.44
Vascular disease 8.33 (0.97–71.3) 0.05 0.62 (0.21–1.82) 0.39 1.16 (0.67–2.00) 0.61
CHA2DS2–VASC Score
a 2.06 (1.27–3.35) 0.004 1.03 (0.77–1.37) 0.85 1.05 (0.90–1.21) 0.57
History of bleeding 0.85 (0.10–7.27) 0.88 1.17 (0.33–4.15) 0.81 2.51 (1.44–4.37) 0.001
HAS-BLED Scorea 1.61 (0.90–2.87) 0.11 1.18 (0.77–1.80) 0.45 1.14 (0.92–1.42) 0.22
Venous thromboembolism 2.26 (0.26–19.4) 0.46 0.87 (0.11–6.64) 0.89 1.29 (0.51–3.26) 0.59
Active cancer/history of cancer 0.04 (0.00–330) 0.48 1.24 (0.35–4.40) 0.74 1.15 (0.62–2.12) 0.66
OAC-naïve at baseline 0.05 (0.00–999) 0.69 0.94 (0.12–7.23) 0.95 0.78 (0.31–1.97) 0.60
Baseline laboratory parameters (hazard ratios per 1 unit increase)
Platelet counta 1.00 (0.99–1.01) 0.71 1.00 (0.99–1.01) 0.60 1.00 (0.99–1.00) 0.34
Hemoglobina 0.80 (0.52–1.22) 0.29 1.05 (0.81–1.37) 0.71 0.89 (0.79–1.02) 0.08
Hematocrita 0.95 (0.81–1.11) 0.51 1.01 (0.91–1.11) 0.86 0.96 (0.92–1.01) 0.11
Leucocyte counta 1.02 (0.91–1.13) 0.77 0.82 (0.63–1.06) 0.12 1.02 (1.00–1.05) 0.041
eGFRa 0.97 (0.93–1.01) 0.17 0.98 (0.96–1.01) 0.21 1.01 (1.00–1.02) 0.27
HbA1ca 1.71 (1.20–2.45) 0.003 1.13 (0.75–1.72) 0.54 1.31 (0.87–1.98) 0.20
Legend: BMI body-mass index, TIA transient ischemic attack, VKA vitamin-K-antagonist, OAC oral anticoagulant, eGFR estimated glomerular filtration rate, 999 as
the upper bound of the 95% confidence interval signifies an abbreviation of a very wide confidence interval, p-values in bold font represent statistically significant
findings, a the hazard ratios for continuous variables are given as per 1 unit increase: age in years, BMI in kg/m2, platelet count in G/l, hemoglobin in g/dl,
hematocrit in %, leucocyte count in G/l, eGFR in ml/min/1.73 m2, HbA1c in rel.%, and D-dimer in μg/ml
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patients may be different from the general population
and that bleeding assessment tools, such as the HAS-
BLED score, should be updated to the DOAC era. Three
patients, without diabetes or previous history of intraoc-
ular or retinal bleeding, suffered from symptomatic,
intraocular hemorrhage during follow-up. Bleeding in
this atypical site has previously been reported in trials
on anticoagulation in AF patients [7], but the high
frequency in this cohort is nonetheless surprising and
may warrant more awareness among physician who treat
patients with anticoagulation.
We further investigated persistence on anticoagulation
treatment in this registry and found that 80 patients
(29.7%) discontinued their baseline anticoagulation over
the course of the follow-up, which translates to a discon-
tinuation rate of 36.9 per 100 patient-years. The majority,
69 of them, switched to a different anticoagulant agent,
but 11 patients discontinued anticoagulation treatment
altogether. We found that after 6 months the drug persist-
ence on the baseline anticoagulant agent was 76.7% and
after 12 months further reduced to 54.7%. The overall per-
sistence in the registry is lower than in some previous re-
ports. While in the pre-DOAC era, discontinuation
frequency had been 26–28% [17, 18], Beyer-Westendorf et
al. reported a persistence rate of 81.5% in patients on
treatment with rivaroxaban after a median treatment time
of 544 days [19]. The most frequent reason for discontinu-
ation of anticoagulation treatment in our registry was per-
manent return to sinus rhythm. This group of patients is
perceived as a low-risk group and especially after success-
ful ablation treatment, anticoagulation treatment is often-
times discontinued in clinical practice [20]. There is,
however, no evidence supporting a discontinuation of
anticoagulation in patients reporting a permanent re-
turn to sinus rhythm, because AF may be asymptom-
atic in nature.
Moreover, we identified novel patient characteristics
that decrease anticoagulation persistence. A history of
bleeding, although not a risk factor for occurrence of
major or CRNM bleeding was a strong risk factor for
discontinuation and the composite of all bleeding events
was the second most frequent reason for anticoagulation
discontinuation. Further, patients with diabetes and in-
creased leucocyte count had increased risk of discontinu-
ation. These patients had to discontinue their baseline
anticoagulation treatment predominately for emerging
chronic medical issues, such as deterioration of kidney
function, coronary heart and peripheral artery disease, and
for safety considerations because of initiation of antiplate-
let medication.
Although our registry was not intended for a direct
comparison of the persistence between different antico-
agulants, our data allow a cautious analysis of drug per-
sistence on VKA and on DOACs. Patients receiving
DOACs were younger, had a higher frequency of previ-
ous bleeding and had more frequently a recent diagnosis
of AF. Nevertheless, patients receiving DOACs did not
have inferior drug persistence compared to patients re-
ceiving VKA. In studies in German and UK primary care
settings, patients on treatment with DOACs even had
better drug persistence than patients on VKA [21, 22].
The benefit of DOACs over VKA concerning persistence
Fig. 1 Cumulative drug persistence over the course of 50 weeks
Table 3 Reasons for discontinuation of first choice anticoagulant
and frequency of alternative choice anticoagulants (N = 80)
Frequency (%)
Reason for discontinuation
Patient-reported permanent return to sinus rhythm 16 (20.0)
Contraindication 12 (15.0)
Physician’s recommendation 10 (12.5)
Difficulty reaching INR 2–3 (VKA only) 9 (11.3)
Major or clinically-relevant non-major bleed 9 (11.3)
Thromboembolism 6 (7.5)
Minor bleeding 5 (6.3)
Renal insufficiency 3 (1.1)
Patient´s wish 3 (1.1)
other 7 (8.8)
Alternative choice anticoagulant
Vitamin-K-Antagonist 16 (20.0)
Dabigatran 8 (10.0)
Rivaroxaban 16 (20.0)
Apixaban 18 (22.5)
LMWH (long-term) 5 (6.3)
None 17 (21.3)
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may have been attenuated in the hospital setting, be-
cause treating physicians were more cautious in the use
of DOACs when new medical complications emerged.
This present investigation was not without limitations.
Patients were not randomized to anticoagulation treatment,
which may have led to a selection bias in the distribution of
comorbidities between DOAC patients and VKA patients.
For example, those patients who remained on VKA treat-
ment during the observation time were likely long-time
VKA users with a stable management of the international-
normalized ratio (INR) and personal positive experience
with VKA use. The study was not suitable for assessing
time in therapeutic range because INR values in between
follow-up visits were not captured. Analysis of safety or effi-
cacy between drug classes were also not permissible
because there was no randomization to anticoagulation
treatment. Patients were referred to the outpatient clinic
for the purposes of study inclusion and not based on any
selection criteria such as high risk of bleeding or stroke.
There may however be an inherent selection bias in the
small sample size. The low sample size further led to wide
confidence interval in the logistic regression analysis.
Members of the registry staff did not actively prescribe
medications or suggest drug discontinuation, nor did they
influence the choice of DOAC. However, in cases of ad-
verse events, patients were encouraged to seek the advice
of a physician who is independent from the registry. We
were unable to analyze if drug persistence was a risk factor
for occurrence of thromboembolic outcomes, because the
follow-up was too short to allow statistical inference.
Low adherence to anticoagulant prescription is poten-
tially associated with increased risk of thromboembol-
ism, but is notoriously difficult to capture and was not
assessed in our investigation. There was no independent
adjudication of study outcomes, but we validated outcomes
internally according to criteria stated in the methods sec-
tion. However, the data quality was ensured by performing
all patient interviews in person with overall very good
patient compliance to study procedures and a low dropout
rate (4.8%).
Conclusion
Patients with AF in this hospital setting had increased
risk of thromboembolism and bleeding, which was medi-
ated by the presence of comorbid conditions, especially
a history of prior cardiovascular or cerebrovascular dis-
eases. Further, anticoagulation treatment was frequently
discontinued due to bleeding or thromboembolic com-
plications, but also due to reasons such as permanent
return to sinus rhythm, patient opinion or physician’s
advice. The risk of thromboembolism in the group of
hospital-patients should not be underestimated and pa-
tients should be encouraged to utilize follow-up visits
specifically concerning anticoagulation treatment in the
first year after anticoagulation initiation.
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